Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
271.65B
Enterprise Value
297.76B
Income
11.03B
Sales
62.38B
Book/sh
33.36
Cash/sh
5.27
Employees
96100
IPO
Oct 17, 2003
P/E
24.79
Forward P/E
15.40
PEG
1.37
P/S
4.35
P/B
5.25
P/C
33.27
P/FCF
26.41
EV/EBITDA
14.21
EV/Sales
4.77
Quick Ratio
0.79
Current Ratio
1.01
Debt/Eq
0.66
LT Debt/Eq
0.56
Option/Short
Yes / Yes
EPS (ttm)
7.07
EPS next Y
11.38
EPS next Q
2.33
EPS this Y
12.12%
EPS next Y
10.76%
EPS next 5Y
11.21%
EPS past 3/5Y
45.90% 22.05%
Sales past 3/5Y
9.82% 16.31%
EPS Y/Y TTM
17.34%
Sales Y/Y TTM
7.32%
EPS Q/Q
23.13%
Sales Q/Q
6.70%
Insider Own
3.44%
Insider Trans
-0.02%
Inst Own
63.33%
Inst Trans
0.75%
ROA
9.41%
ROE
22.60%
ROIC
13.70%
Gross Margin
74.11%
Oper. Margin
23.31%
Profit Margin
17.68%
SMA20
-3.43%
SMA50
2.78%
SMA200
-2.72%
Trades
Shs Outstand
1.55B
Shs Float
1.50B
52W High
212.71 -17.66%
52W Low
153.41 14.17%
Volatility
1.52% 1.83%
ATR (14)
4.11
RSI (14)
45.40
Beta
0.30
Rel Volume
0.94
Avg Volume
3.00M
Volume
1,657,365
Perf Week
-5.00%
Perf Month
3.98%
Perf Quarter
5.53%
Perf Half Y
-7.69%
Perf YTD
-0.20%
Perf Year
-2.59%
Perf 3Y
36.84%
Perf 5Y
55.56%
Perf 10Y
224.36%
Prev Close
178.76
Price
175.15
Change %
-2.02%
Consensus
Buy
Avg. Price Target
$228.71
Implied Upside
+30.6%
Analysts3incl. previous ratings
Rating Distribution1 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 15, 2026Upgrade
DB logoDDeutsche Bank
Sell → Hold
Sep 09, 2026Initiated
RY logoRRBC Capital Mkts
Outperform
Jul 13, 2026Downgrade
HSBC logoHHSBC Securities
Buy → Hold
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sharma ManiSee RemarksAug 08 '26Buy160.57203,24919,288Sep 11 04:05 PM
Sharma ManiSee RemarksMay 20 '26Sale185.7811,8932,209,48219,262May 22 04:05 PM
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.
M.B.A.Mr. Pascal Claude Roland Soriot D.V.M.
CFO & Executive DirectorDr. Aradhana Sarin M.D.
EVP of Global opt. & ITMs. Pam P. Cheng
Head of Investor RelationsMr. Joris Silon
CHROMr. Jeffrey Pott J.D.